Literature DB >> 1506631

Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis.

U Beuers1, U Spengler, M Sackmann, G Paumgartner, T Sauerbruch.   

Abstract

Complications of endoscopic retrograde cholangiography specific to patients with primary sclerosing cholangitis have not yet been reported. We observed transient rises of serum bilirubin after diagnostic endoscopic retrograde cholangiography in five of 15 patients and persistent rises in three of 15 patients with primary sclerosing cholangitis examined consecutively by endoscopic retrograde cholangiography from 1985 to 1990. Deterioration of cholestasis was particularly associated with advanced disease. Seven of eight patients with deterioration after endoscopic retrograde cholangiography had septal fibrosis (stage III) or cirrhosis (stage IV) and a priori elevated serum bilirubin levels. In contrast, all patients with no deterioration of cholestasis following endoscopic retrograde cholangiography had early histological changes (stage I-II), and all but one patient had normal serum bilirubin levels. We conclude that the potentially harmful effects on biliary excretion must be taken into account when the use of endoscopic retrograde cholangiography is being considered in patients with advanced primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506631     DOI: 10.1016/0168-8278(92)90026-l

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  2 in total

1.  The best approach for diagnosing primary sclerosing cholangitis.

Authors:  Wellington Andraus; Luciana Haddad; Lucas Souto Nacif; Felipe D Silva; Roberto Blasbalg; Luiz Augusto Carneiro D'Albuquerque
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

2.  Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.

Authors:  Moritz Peiseler; David Reiners; Hans O Pinnschmidt; Marcial Sebode; Franziska Jung; Johannes Hartl; Roman Zenouzi; Hanno Ehlken; Stefan Groth; Guido Schachschal; Thomas Rösch; Christina Weiler-Normann; Ansgar W Lohse; Christoph Schramm
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.